PTP1B, A Potential Target of Type 2 Diabetes MellitusJia Sun1,2, Chao Qu1,2,3, Yajun Wang1,2, Hui Huang1,2, Mingrui Zhang1,2, Hongyan Li1,2, Yejun Zhang1,2, Yang Wang4 and Wei Zou1,2*
- *Corresponding Author:
- Wei Zou
Liaoning Key Laboratories of Biotechnology and Molecular Drug Research and Development
Dalian, 116081, China
E-mail: [email protected]
Received date September 01, 2016; Accepted date September 13, 2016; Published date September 21, 2016
Citation: Sun J, Qu C, Wang Y, Huang H, Zhang M, et al. (2016) PTP1B, A Potential Target of Type 2 Diabetes Mellitus. Mol Biol 5:174. doi:10.4172/2168-9547.1000174
Copyright: © 2016 Sun J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Diabetes is one of the common metabolic diseases, mainly divided into two types, type 1 diabetes mellitus and type 2 diabetes mellitus. Insulin resistance is the main performance of type 2 diabetes mellitus which are relative to some gene mutation, genetics, obesity and so on. Protein-tyrosine phosphatase 1B (PTP1B) plays an important role as a negative regulator in insulin signaling pathways that are implicated in metabolic diseases such as obesity and type 2 diabetes. Many evidences from clinical and basic researches show that the high expression of PTP1B induces insulin resistance. It appears that PTP1B is an effective target for the treatment of type 2 diabetes mellitus. In this review, we briefly introduce composition of PTP1B and the role of PTP1B in insulin signaling of type 2 diabetes mellitus. We also summarized recent research progress of PTP1B inhibitors used in therapy of type 2 diabetes mellitus.